Citigroup downgraded Moderna from Hold to Sell, citing that the stock's recent surge is not supported by its current cancer vaccine pipeline. Despite a 590% rise in 2026, Citi's analyst raised the price target to $80, still well below Moderna's trading price around $203.46. The downgrade focuses on uncertainties about the broad effectiveness of Moderna's personalized cancer vaccine, developed with Merck, with more data expected in October. Meanwhile, Merck and Pfizer stocks showed little change, highlighting Moderna's unique volatility amid the biotech rally.
Moderna shares are down 6.17% on Pluang, trading at USD 190.91 as of Sep 30, 2026 20:51 WIB, reflecting notable volatility compared to Merck and Pfizer, which are relatively stable with 1-day changes of -0.82% and -0.33% respectively. Merck trades at USD 148.09 and Pfizer at USD 28.63, with strong buy interest on the platform.
Moderna's stock fell about 7.4% following the release of Phase 3 trial data for its experimental cancer vaccine, intismeran, developed with Merck. The results tempered investor enthusiasm, reflecting that expectations had been very high. Merck's shar...
Moderna's stock fell 7% after its personalized melanoma vaccine, despite meeting its primary goal in a late-stage trial, showed less impact on distant cancer spread than earlier studies suggested. This has led investors to reassess the commercial pot...
Biotech stocks are rallying strongly in 2026, with the iShares Biotechnology ETF up 24% year-to-date, building on a 28% gain in 2025. Moderna leads with a 587% surge despite a recent dip after positive cancer vaccine data leaked. The sector's growth ...
Moderna and Merck released Phase 3 trial results showing their personalized mRNA cancer vaccine, combined with Keytruda, reduces melanoma recurrence or death risk by 42% compared to Keytruda alone. Specialists see this as a significant breakthrough t...
Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the result...
